Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Here’s Why

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw an uptick in trading volume on Tuesday . 160,500 shares were traded during trading, an increase of 77% from the previous session’s volume of 90,926 shares.The stock last traded at $4.5850 and had previously closed at $4.55.

Analyst Upgrades and Downgrades

IVA has been the subject of several research reports. Wall Street Zen raised shares of Inventiva to a “hold” rating in a report on Saturday, October 18th. Guggenheim lowered their price target on Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Wolfe Research raised Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Wednesday, October 8th. Finally, HC Wainwright boosted their price target on Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Inventiva currently has a consensus rating of “Moderate Buy” and an average target price of $17.33.

Inventiva Price Performance

The firm has a 50 day moving average price of $4.42 and a 200 day moving average price of $4.39.

Institutional Investors Weigh In On Inventiva

Several large investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC lifted its position in Inventiva by 54.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after purchasing an additional 5,843 shares during the last quarter. Creative Planning purchased a new stake in shares of Inventiva during the 2nd quarter valued at about $32,000. NewEdge Advisors LLC bought a new position in shares of Inventiva in the 3rd quarter valued at about $116,000. Finally, Millennium Management LLC purchased a new position in Inventiva in the third quarter worth about $649,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.